Intellipharmaceutics International Inc. (IPCI)

[JJAAMMAANN]

Cut from an old interview...
Are there any other products you’d like to talk about that are in the midst of development?
Dr. Odidi: Yes, in addition to the 15 products that are currently in our pipeline, we are constantly looking for opportunities where we can exploit the Hypermatrix technology and our internal expertise. It is well known that there are many patent expirations threatening major products for most large pharmaceutical companies. This is a huge opportunity for us. As such, we are actively seeking to license our proprietary drug delivery platforms to owners of patented, branded multiple-dose-per-day products. The natural life cycle of those products can potentially be extended far beyond the expiry of the underlying patents, when ordinarily generic introductions might be expected to cause substantial sales erosion. The development of a proprietary controlled-release formulation for sale under the banner of the original, established brand is a sound brand management strategy which pharmaceutical companies often consider long before the expiry of the patents. We will also continue to seek opportunities for developing difficult-to-formulate generics and applying our technology to the development of new products where the benefits of the application of our technology would provide a clear competitive advantage, similar to what we are doing with our Rexista product.

http://files.shareholder.com/downloads/ABEA-43EQSZ/3895216196x0x360649/37C6C105-9C30-4E8F-8026-DD017F961618/IntelliPharmaCeutics.pdf